Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC8052	AZ5104 Featured	AZ5104 is an active circulating metabolite of AZD9291.
DC7926	AZ-6102 Featured	AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows 5 nM Wnt pathway inhibition in DLD-1 cells.
DC8842	AZ-7371（DprE1-IN-1） Featured	AZ-7371（DprE1-IN-1） is a novel non-covalent DprE1 inhibitor.
DC12677	AZ876 Featured	AZ876 is a novel high-affinity LXR agonist.
DC10056	AZ9482 Featured	AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine.
DCAPI1182	Azathioprine (Azasan, Imuran) Featured	Azathioprine (Azasan, Imuran) is the analytical standard of Azathioprine. This product is intended for research and analytical applications. Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis.
DC20726	AZD 4205 Featured	AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo.
DC20729	AZD 5991 Featured	AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity.
DC9309	AZD-0156 Featured	AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities.
DC20002	AZD-0284 Featured	AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.
DC11481	AZD-0364 Featured	AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.
DC10534	AZD0865(Linaprazan) Featured	AZD0865 is a potent agent that inhibits gastric H(+),K(+)-ATPase activity and acid formation in vitro, with a fast onset of effect.
DC5054	AZD1080 Featured	AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.
DC7060	AZD1152 Featured	AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM.
DC5012	AZD-1208 Featured	AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.
DC9731	AZD1283 Featured	AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.
DC20162	AZD1390 Featured	AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases
DC5032	AZD1480 Featured	AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.
DC7572	AZD1981 Featured	AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1
DC10724	AZD2098 Featured	AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research.
DC1037	AZD2461 Featured	AZD2461 is indeed a novel poly (ADP-ribose) polymerase (PARP) inhibitor that has been investigated for its potential to overcome resistance mechanisms associated with other PARP inhibitors, such as Olaparib. One of the key resistance mechanisms to Olaparib is mediated by P-glycoprotein (Pgp), an efflux pump that can reduce intracellular concentrations of the drug, thereby diminishing its efficacy.
DC7748	AZD-26(AKT-IN-1） Featured	AZD-26 is an inhibitor of AKT. AZD-26 inhibits the phosphorylation of Thr308 on AKT in BT474 cells with an IC50 of 422 nM.
DC6302	AZD2858 Featured	AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.
DC7799	AZD2932 Featured	AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR.
DC20129	AZD3229 Featured	AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
DC7074	AZD-3463 Featured	AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
DC8472	AZD-3759 Featured	AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity.
DC8400	AZD3839 Featured	AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
DC9263	AZD-3965 Featured	AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
DC1075	AZD4547 Featured	AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively.

Featured products

Customized Consultation X

Your information is safe with us. * Required Fields.